Gentry Leesa 4
4 · RenovoRx, Inc. · Filed Apr 7, 2026
Research Summary
AI-generated summary of this filing
RenovoRx (RNXT) CCO Leesa Gentry Receives Option Award
What Happened
Leesa Gentry, Chief Clinical Officer of RenovoRx, was granted stock options covering 128,550 shares on April 3, 2026. The grant has no immediate cash value to the reporting person (acquisition price reported as $0). The options consist of 66,954 incentive stock options (ISOs) and 61,596 non-qualified stock options (NQSOs). Vesting occurs monthly over four years (1/48 per month) with no cliff, vesting effective from January 1, 2026; the options become fully vested on January 1, 2030 and expire April 3, 2036.
Key Details
- Transaction date: April 3, 2026; Form 4 filed April 7, 2026 (timely under SEC two-business-day rule).
- Grant size: 128,550 options (66,954 ISOs; 61,596 NQSOs). Reported acquisition price: $0 (derivative award).
- Vesting: Monthly at 1/48 per month, vesting start date January 1, 2026; fully vested January 1, 2030.
- Exercisability condition: Options will only become exercisable if there is an effective registration statement covering the underlying shares.
- Shares owned after transaction: Not specified in this filing.
- Footnote: Grant approved by the Compensation Committee (see footnote F1). No tax-withholding, 10b5-1 plan, or sale reported.
Context
This is a compensation-related option grant (an award), not a purchase or sale of existing shares. Because these are options, they do not represent immediate share ownership or cash proceeds until (1) the company has an effective registration statement permitting exercise and sale, and (2) the options are exercised. Such grants are common for executive compensation and are informational rather than direct market bets.
Insider Transaction Report
- Award
Stock Option
[F1]2026-04-03+128,550→ 128,550 totalExercise: $0.98→ Common Stock (128,550 underlying)
Footnotes (1)
- [F1]On April 3, 2026, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 128,550 shares of the Issuer's common stock (66,954 shares of which are underlying incentive stock options and 61,596 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2026. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2030, and will expire on April 3, 2036.